Eribulin for the treatment of advanced breast cancer: A prospective observational registry study

Menée au Royaume-Uni dans un contexte de vie réelle à partir de données portant sur 76 patientes atteintes d'un cancer du sein de stade localement avancé ou métastatique, cette étude multicentrique observationnelle évalue l'efficacité, du point de vue du taux de réponse, du délai avant progression et de la survie globale, et la toxicité de l'éribuline

Résumé en anglais

Objective : Eribulin treatment improved overall survival with predictable toxicities in phase 3 trials of patients with previously treated, locally advanced/metastatic breast cancer. This study (NCT02443428) prospectively observed eribulin-treated patients in real-world clinical practice.

Methods : This observational multicentre registry study enrolled 76 patients with locally advanced/metastatic breast cancer who had ≤2 prior chemotherapeutic regimens for advanced disease. Eribulin was administered at a 1.23 mg/m2 dose (days 1 and 8 of every 21-day cycle). Adverse events (AEs) were monitored and effectiveness was assessed per local practice.

Results : AEs occurred in 98.7% of patients; 88.2% had eribulin-related AEs. The most common AEs were fatigue (64.5%), alopecia (36.8%), nausea (35.5%) and constipation (30.3%). Serious AEs occurred in 42.1% of patients. The most common grade 3/4 AEs were neutropenia (9.2%), febrile neutropenia (9.2%), dyspnoea (5.3%) and pleural effusion (5.3%). No fatal AEs occurred. Dose reductions occurred in 31.6% of patients, 42.1% experienced dose delays and 9.2% discontinued due to worsening condition. There were complete responses in 2.6% and partial responses in 15.8% of patients. Median time to progression and overall survival were 4.0 and 8.3 months, respectively.

Conclusion : Eribulin was well tolerated in real-world clinical practice, comparable to safety and effectiveness reported in other clinical trials.